company background image
A083790 logo

CrystalGenomics Invites KOSDAQ:A083790 Stock Report

Last Price

₩3.66k

Market Cap

₩274.7b

7D

-6.2%

1Y

11.2%

Updated

28 Mar, 2024

Data

Company Financials

CrystalGenomics Invites Co., LTD.

KOSDAQ:A083790 Stock Report

Market Cap: ₩274.7b

A083790 Stock Overview

CrystalGenomics Invites Co., LTD., a biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea.

A083790 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

CrystalGenomics Invites Co., LTD. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CrystalGenomics Invites
Historical stock prices
Current Share Price₩3,660.00
52 Week High₩5,950.00
52 Week Low₩2,455.00
Beta-0.051
1 Month Change-1.08%
3 Month Change31.89%
1 Year Change11.25%
3 Year Change-59.56%
5 Year Change-68.17%
Change since IPO-53.43%

Recent News & Updates

CrystalGenomics Invites Co., LTD.'s (KOSDAQ:083790) Share Price Is Matching Sentiment Around Its Revenues

Mar 19
CrystalGenomics Invites Co., LTD.'s (KOSDAQ:083790) Share Price Is Matching Sentiment Around Its Revenues

Recent updates

CrystalGenomics Invites Co., LTD.'s (KOSDAQ:083790) Share Price Is Matching Sentiment Around Its Revenues

Mar 19
CrystalGenomics Invites Co., LTD.'s (KOSDAQ:083790) Share Price Is Matching Sentiment Around Its Revenues

Is CrystalGenomics (KOSDAQ:083790) Using Debt Sensibly?

Jan 28
Is CrystalGenomics (KOSDAQ:083790) Using Debt Sensibly?

Update: CrystalGenomics (KOSDAQ:083790) Stock Gained 57% In The Last Five Years

Dec 06
Update: CrystalGenomics (KOSDAQ:083790) Stock Gained 57% In The Last Five Years

Shareholder Returns

A083790KR BiotechsKR Market
7D-6.2%1.4%2.4%
1Y11.2%21.6%12.2%

Return vs Industry: A083790 underperformed the KR Biotechs industry which returned 21.6% over the past year.

Return vs Market: A083790 matched the KR Market which returned 12.2% over the past year.

Price Volatility

Is A083790's price volatile compared to industry and market?
A083790 volatility
A083790 Average Weekly Movement10.6%
Biotechs Industry Average Movement8.0%
Market Average Movement5.2%
10% most volatile stocks in KR Market11.9%
10% least volatile stocks in KR Market2.4%

Stable Share Price: A083790's share price has been volatile over the past 3 months.

Volatility Over Time: A083790's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
200068Joong-Myung Chohttps://www.cgxinc.com

CrystalGenomics Invites Co., LTD., a biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea. It offers Acelex® (polmacoxib), an anti-inflammatory and pain relief drug, as well as CG-650, an anti-inflammatory drug, currently under phase 1 stage for the treatment of osteoarthritis; CG-651, an anti-inflammatory drug, currently under phase 1 stage for the treatment of neuropathic pain; and CG-652, an anti-inflammatory drug, currently under phase 1 stage for the treatment of rheumatoid arthritis. The company is also involved in the development of Ivaltinostat, an anti-cancer drug, currently under phase 2 stage for the treatment of pancreatic cancer and myelodysplastic syndrome, as well as preclinical stage for the treatment of acute myeloid leukemia and hepatocellular carcinoma; Camrelizumab, an anti-cancer drug, currently under phase 3 stage for the treatment of NSCLC; and Luxeptinib, an anti-cancer drug, currently under phase 1 stage for the treatment of acute myeloid leukemia, chronic lymphocytic leukemia, and non-hodgkin’s lymphoma.

CrystalGenomics Invites Co., LTD. Fundamentals Summary

How do CrystalGenomics Invites's earnings and revenue compare to its market cap?
A083790 fundamental statistics
Market cap₩274.70b
Earnings (TTM)-₩47.09b
Revenue (TTM)₩4.88b

56.3x

P/S Ratio

-5.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A083790 income statement (TTM)
Revenue₩4.88b
Cost of Revenue₩3.42b
Gross Profit₩1.46b
Other Expenses₩48.55b
Earnings-₩47.09b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-627.45
Gross Margin29.86%
Net Profit Margin-965.29%
Debt/Equity Ratio26.7%

How did A083790 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.